Prague Med. Rep. 2021, 122, 243-256
https://doi.org/10.14712/23362936.2021.22
Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients
Crossref Cited-by Linking
- Posocco Bianca, Zanchetta Martina, Orleni Marco, Gagno Sara, Montico Marcella, Peruzzi Elena, Roncato Rossana, Gerratana Lorenzo, Corsetti Serena, Puglisi Fabio, Toffoli Giuseppe: Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method. Therapeutic Drug Monitoring 2024. <https://doi.org/10.1097/FTD.0000000000001174>
- van der Kleij Maud B. A., Guchelaar Niels A. D., Mathijssen Ron H. J., Versluis Jurjen, Huitema Alwin D. R., Koolen Stijn L. W., Steeghs Neeltje: Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clin Pharmacokinet 2023, 62, 1333. <https://doi.org/10.1007/s40262-023-01293-9>
- Burke Sarah M., Kamal Mustafa, Goey Andrew K. L.: Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma. Therapeutic Drug Monitoring 2023, 45, 327. <https://doi.org/10.1097/FTD.0000000000001063>
- Hulin Anne, Gelé Thibaut, Fenioux Charlotte, Kempf Emmanuelle, Sahali Dil, Tournigand Christophe, Ollero Mario: Pharmacology of Tyrosine Kinase Inhibitors. CJASN 2023. <https://doi.org/10.2215/CJN.0000000000000395>
- Hirabatake Masaki, Mizuno Tomoyuki, Kato Hironori, Hashida Tohru: Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer. Front. Pharmacol. 2022, 13. <https://doi.org/10.3389/fphar.2022.984002>
